Article Text

Download PDFPDF

460 Discovery of potent Cbl-b inhibitors demonstrating enhanced immune cell activity and tumor growth inhibition in murine syngeneic models
  1. Silvana Leit and
  2. David Ciccone
  1. Nimbus Therapeutics, Cambridge, MA, United States


Background Casitas B-lineage lymphoma b (Cbl-b), a RING finger E3 ligase and a member of a highly conserved family of Cbl proteins, catalyzes the ubiquitination of substrate proteins to regulate multiple signaling events in a variety of cell types, including immune cells. In T cells, Cbl-b negatively regulates adaptive immune system signaling by establishing the threshold for the activation of antigen receptors. Additionally, Cbl-b regulates the function of other immune cell types, including NK cells, dendritic cells (DC) and monocytes. Cbl-b deficient T cells no longer require a costimulatory signal to be fully activated. Cbl-b KO mice spontaneously reject tumors via an enhanced immune response. Taken together, these findings point to Cbl-b inhibitors as having the potential to be highly efficacious immuno-oncology agents.

Methods A structure-based drug design approach was used to identify potent inhibitors of Cbl-b. Biochemical and biophysical assays, in vitro cellular assays, as well as primary human and mouse immune cell assays assays were used to profile inhibitor compounds. In vivo activity of Cbl-b inhibitors was evaluated using an anti-CD3 mouse model and a CT-26 syngeneic mouse model.

Results Cbl-b inhibitors potently bind to Cbl-b, preventing Cbl-b phosphorylation and binding to E2. In cells, compound treatment results in enhanced transcriptional activity and robust cytokine secretion from primary human and mouse T cells. In vivo, an increase in cytokines and T cell activation markers was observed after a single dose of compound. Repeated dosing of compound showed dose-dependent anti-tumor activity in the colorectal CT-26 syngeneic model.

Conclusions Potent Cbl-b inhibitors demonstrate strong T cell activation and anti-tumor activity in a syngeneic tumor model. These data support Cbl-b inhibitors as a promising therapeutic opportunity for cancer treatment.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.